» Articles » PMID: 37928498

Epidemiology, Clinical Presentation and Treatment Outcomes in Patients with COVID-19 in an Ambulatory Setting: a Cross Sectional Study During the Massive SARS-CoV-2 Wave in India

Overview
Journal Bioinformation
Specialty Biology
Date 2023 Nov 6
PMID 37928498
Authors
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic, caused by SARS-CoV-2, has profoundly affected developing countries like India. This retrospective cross-sectional analysis investigated epidemiological, clinical characteristics, treatment strategies, and outcomes for hospitalized COVID-19 patients during the Massive SARS-CoV-2 Wave in India. Among 233 patients, the median age was 47.33 years, mostly male. Hospital stays averaged 8.4 days. Common symptoms include fever (88.41%), dry cough (56.2%), myalgia (44.20%), and shortness of breath (22.8%). The most common comorbidities were diabetes mellitus (52%) and hypertension (47.2%). Elevated biomarkers include D-dimer (24.4%), CRP (32.1%), ferritin (26.60%), and others. Prescription analysis revealed that antibiotics (42.6%), Antivirals (37%), anthelmintics (20.30%), vitamins and nutritional supplements (20.71%) and glucocorticoids (12.8%) were the most commonly prescribed. Oxygen therapy was needed by 19.31% of patients in the moderate and severe categories within 24 hours of admission. The mortality rate was 8.58%. The surge led to increased hospitalizations and mortality, particularly among young adults. Diabetes and hypertension were correlated with mortality. Irregular use of drugs lacking evidence, like antibiotics and anthelmintics, vitamins and nutritional supplements, was observed in COVID-19 management. This study underscores the impact of the pandemic in India and highlights the need for evidence-based treatments.

References
1.
Manomaipiboon A, Pholtawornkulchai K, Poopipatpab S, Suraamornkul S, Maneerit J, Ruksakul W . Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Trials. 2022; 23(1):714. PMC: 9412770. DOI: 10.1186/s13063-022-06649-3. View

2.
Phan L, Nguyen T, Luong Q, Nguyen T, Nguyen H, Le H . Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020; 382(9):872-874. PMC: 7121428. DOI: 10.1056/NEJMc2001272. View

3.
Chenchula S, Amerneni K, Ghanta M, Padmavathi R, Chandra M, Adusumilli M . Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review. Virology. 2023; 584:38-43. PMC: 10197433. DOI: 10.1016/j.virol.2023.04.007. View

4.
Chhabra S, Sethi S, Kaur S, Singla M, Jindal J, Midha V . Clinical Profile of Coronavirus Disease 2019 Comparing the First and Second Waves: A Single-Center Study from North India. Int J Appl Basic Med Res. 2022; 12(2):95-102. PMC: 9215178. DOI: 10.4103/ijabmr.ijabmr_691_21. View

5.
Kumar G, Mukherjee A, Sharma R, Menon G, Sahu D, Wig N . Clinical profile of hospitalized COVID-19 patients in first & second wave of the pandemic: Insights from an Indian registry based observational study. Indian J Med Res. 2021; 153(5&6):619-628. PMC: 8555588. DOI: 10.4103/ijmr.ijmr_1628_21. View